Stay updated with breaking news from Mcscc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has issued a complete response letter to the biologic license application seeking the approval of cosibelimab for use in patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. ....
Perioperative treatment with cemiplimab continued to produce signs of efficacy in patients with resectable stage II to IV cutaneous squamous cell carcinoma. ....
1. In this Norwegian study, patients receiving organ transplants with cutaneous squamous cell carcinoma (cSCC) had higher rates of developing a second cSCC, metastasis, and death from cSCC when compared to patients with cSCC not receiving organ transplants. 2. In order to ensure proper follow-up and skin cancer care policies, clinicians should be aware of ....
Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future. ....